MARKET

ATYR

ATYR

Atyr Pharma Inc
NASDAQ
0.2872
-0.0069
-2.35%
After Hours: 0.2820 -0.0052 -1.81% 19:56 10/02 EDT
OPEN
0.2872
PREV CLOSE
0.2941
HIGH
0.2960
LOW
0.2815
VOLUME
1.98M
TURNOVER
--
52 WEEK HIGH
1.120
52 WEEK LOW
0.2720
MARKET CAP
28.17M
P/E (TTM)
-0.4613
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ATYR last week (0921-0925)?
Weekly Report · 6d ago
Positive FDA Alignment Boosts ATyr Pharma's Rare Lung Disease
Benzinga · 09/24 17:31
Why is aTyr Pharma Stock (ATYR) Down 7% Today?
TipRanks · 09/24 15:49
Analysts Offer Insights on Healthcare Companies: Aytu BioScience (AYTU), Surrozen (SRZN) and aTyr Pharma (ATYR)
TipRanks · 09/24 15:21
ATYR Stock In Focus After FDA Alignment On Efzofitimod Phase 3
NASDAQ · 09/24 14:21
aTyr Pharma Aligns with FDA on Efzofitimod Phase 3
TipRanks · 09/24 13:41
aTyr Pharma Reaches FDA Alignment On Protocol For A Phase 3 Study Of Its Lead Therapeutic Candidate Efzofitimod In Patients With Chronic, Symptomatic Pulmonary Sarcoidosis With Restrictive Lung Disease; Expects To Initiate Study-Related Activities In Q4 2026
Benzinga · 09/24 10:07
Weekly Report: what happened at ATYR last week (0914-0918)?
Weekly Report · 09/21 09:09
More
About ATYR
aTyr Pharma, Inc. is a clinical-stage biotechnology company. The Company is leveraging evolutionary intelligence to translate tRNA synthetase biology into new therapies for fibrosis and inflammation. Its lead therapeutic candidate is efzofitimod, a first-in-class biologic immunomodulator in clinical development for the treatment of interstitial lung disease (ILD), a group of immune-mediated disorders that can cause inflammation and fibrosis, or scarring, of the lungs. Efzofitimod is a tRNA synthetase-derived therapy that selectively modulates activated myeloid cells through neuropilin-2 (NRP2) to resolve aberrant inflammation without immune suppression and potentially prevent the progression of fibrosis. ATYR0101 is a fusion protein derived from a domain of aspartyl-tRNA synthetase (DARS). ATYR0750 is a fusion protein derived from the domain of alanyl-tRNA synthetase (AARS). ATYR0750 is a novel ligand to fibroblast growth factor receptor 4 (FGFR4).

Webull offers aTyr Pharma Inc stock information, including NASDAQ: ATYR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATYR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ATYR stock methods without spending real money on the virtual paper trading platform.